APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Inhalable Biologics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Respiratory Inhalable Biologics Market Analysis and Forecast 2026-2032

8 January 2026194 pages

Choose your research edition.

Industry ResearchRespiratory Inhalable Biologics Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Inhalable Biologics Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Respiratory Inhalable Biologics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Inhalable Biologics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Inhalable Biologics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Respiratory Inhalable Biologics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Respiratory Inhalable Biologics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Respiratory Inhalable Biologics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Respiratory Inhalable Biologics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Respiratory Inhalable Biologics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Respiratory Inhalable Biologics include GSK, AstraZeneca, Boehringer Ingelheim, Vertex, Roche, Novartis, Chiesi, Teva and Prasco Laboratories, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Respiratory Inhalable Biologics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Respiratory Inhalable Biologics, also provides the sales of main regions and countries. Of the upcoming market potential for Respiratory Inhalable Biologics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Respiratory Inhalable Biologics sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Respiratory Inhalable Biologics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Respiratory Inhalable Biologics sales, projected growth trends, production technology, application and end-user industry.

Respiratory Inhalable Biologics Segment by Company

GSK

AstraZeneca

Boehringer Ingelheim

Vertex

Roche

Novartis

Chiesi

Teva

Prasco Laboratories

Viatris

Amgen

Sumitomo Dainippon

Zhengdatianqing

Merck

Respiratory Inhalable Biologics Segment by Type

Protein Drugs

Peptide Drugs

Monoclonal Antibodies

Others

Respiratory Inhalable Biologics Segment by Application

Hospital

Retail Pharmacy

Others

Respiratory Inhalable Biologics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Inhalable Biologics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Inhalable Biologics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Inhalable Biologics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Respiratory Inhalable Biologics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Respiratory Inhalable Biologics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Respiratory Inhalable Biologics sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Respiratory Inhalable Biologics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Protein Drugs Major Manufacturers Table 3. Peptide Drugs Major Manufacturers Table 4. Monoclonal Antibodies Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Respiratory Inhalable Biologics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Retail Pharmacy Major Manufacturers Table 9. Others Major Manufacturers Table 10. Respiratory Inhalable Biologics Industry Trends Table 11. Respiratory Inhalable Biologics Industry Drivers Table 12. Respiratory Inhalable Biologics Industry Opportunities and Challenges Table 13. Respiratory Inhalable Biologics Industry Restraints Table 14. Global Respiratory Inhalable Biologics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Respiratory Inhalable Biologics Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Respiratory Inhalable Biologics Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Respiratory Inhalable Biologics Revenue Market Share by Region (2021-2026) Table 18. Global Respiratory Inhalable Biologics Revenue Market Share by Region (2027-2032) Table 19. Global Respiratory Inhalable Biologics Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units ) Table 20. Global Respiratory Inhalable Biologics Sales by Region (2021-2026) & (k units ) Table 21. Global Respiratory Inhalable Biologics Sales by Region (2027-2032) & (k units ) Table 22. Global Respiratory Inhalable Biologics Sales Market Share by Region (2021-2026) Table 23. Global Respiratory Inhalable Biologics Sales Market Share by Region (2027-2032) Table 24. Global Respiratory Inhalable Biologics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Respiratory Inhalable Biologics Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Respiratory Inhalable Biologics Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Respiratory Inhalable Biologics Sales Market Share by Manufacturers (2021-2026) Table 28. Global Respiratory Inhalable Biologics Sales Price (USD/unit) of Manufacturers (2021-2026) Table 29. Global Respiratory Inhalable Biologics Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Respiratory Inhalable Biologics Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Respiratory Inhalable Biologics Manufacturers, Product Type & Application Table 32. Global Respiratory Inhalable Biologics Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Respiratory Inhalable Biologics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Respiratory Inhalable Biologics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Respiratory Inhalable Biologics Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Respiratory Inhalable Biologics Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Respiratory Inhalable Biologics Revenue Market Share by Type (2021-2026) Table 39. Global Respiratory Inhalable Biologics Revenue Market Share by Type (2027-2032) Table 40. Global Respiratory Inhalable Biologics Sales by Type 2021 VS 2025 VS 2032 (k units ) Table 41. Global Respiratory Inhalable Biologics Sales by Type (2021-2026) & (k units ) Table 42. Global Respiratory Inhalable Biologics Sales by Type (2027-2032) & (k units ) Table 43. Global Respiratory Inhalable Biologics Sales Market Share by Type (2021-2026) Table 44. Global Respiratory Inhalable Biologics Sales Market Share by Type (2027-2032) Table 45. Global Respiratory Inhalable Biologics Price by Type (2021-2026) & (USD/unit) Table 46. Global Respiratory Inhalable Biologics Price by Type (2027-2032) & (USD/unit) Table 47. Global Respiratory Inhalable Biologics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Respiratory Inhalable Biologics Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Respiratory Inhalable Biologics Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Respiratory Inhalable Biologics Revenue Market Share by Application (2021-2026) Table 51. Global Respiratory Inhalable Biologics Revenue Market Share by Application (2027-2032) Table 52. Global Respiratory Inhalable Biologics Sales by Application 2021 VS 2025 VS 2032 (k units ) Table 53. Global Respiratory Inhalable Biologics Sales by Application (2021-2026) & (k units ) Table 54. Global Respiratory Inhalable Biologics Sales by Application (2027-2032) & (k units ) Table 55. Global Respiratory Inhalable Biologics Sales Market Share by Application (2021-2026) Table 56. Global Respiratory Inhalable Biologics Sales Market Share by Application (2027-2032) Table 57. Global Respiratory Inhalable Biologics Price by Application (2021-2026) & (USD/unit) Table 58. Global Respiratory Inhalable Biologics Price by Application (2027-2032) & (USD/unit) Table 59. GSK Company Information Table 60. GSK Business Overview Table 61. GSK Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 62. GSK Respiratory Inhalable Biologics Product Portfolio Table 63. GSK Recent Development Table 64. AstraZeneca Company Information Table 65. AstraZeneca Business Overview Table 66. AstraZeneca Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 67. AstraZeneca Respiratory Inhalable Biologics Product Portfolio Table 68. AstraZeneca Recent Development Table 69. Boehringer Ingelheim Company Information Table 70. Boehringer Ingelheim Business Overview Table 71. Boehringer Ingelheim Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 72. Boehringer Ingelheim Respiratory Inhalable Biologics Product Portfolio Table 73. Boehringer Ingelheim Recent Development Table 74. Vertex Company Information Table 75. Vertex Business Overview Table 76. Vertex Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 77. Vertex Respiratory Inhalable Biologics Product Portfolio Table 78. Vertex Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 82. Roche Respiratory Inhalable Biologics Product Portfolio Table 83. Roche Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Novartis Respiratory Inhalable Biologics Product Portfolio Table 88. Novartis Recent Development Table 89. Chiesi Company Information Table 90. Chiesi Business Overview Table 91. Chiesi Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Chiesi Respiratory Inhalable Biologics Product Portfolio Table 93. Chiesi Recent Development Table 94. Teva Company Information Table 95. Teva Business Overview Table 96. Teva Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Teva Respiratory Inhalable Biologics Product Portfolio Table 98. Teva Recent Development Table 99. Prasco Laboratories Company Information Table 100. Prasco Laboratories Business Overview Table 101. Prasco Laboratories Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Prasco Laboratories Respiratory Inhalable Biologics Product Portfolio Table 103. Prasco Laboratories Recent Development Table 104. Viatris Company Information Table 105. Viatris Business Overview Table 106. Viatris Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Viatris Respiratory Inhalable Biologics Product Portfolio Table 108. Viatris Recent Development Table 109. Amgen Company Information Table 110. Amgen Business Overview Table 111. Amgen Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Amgen Respiratory Inhalable Biologics Product Portfolio Table 113. Amgen Recent Development Table 114. Sumitomo Dainippon Company Information Table 115. Sumitomo Dainippon Business Overview Table 116. Sumitomo Dainippon Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Sumitomo Dainippon Respiratory Inhalable Biologics Product Portfolio Table 118. Sumitomo Dainippon Recent Development Table 119. Zhengdatianqing Company Information Table 120. Zhengdatianqing Business Overview Table 121. Zhengdatianqing Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Zhengdatianqing Respiratory Inhalable Biologics Product Portfolio Table 123. Zhengdatianqing Recent Development Table 124. Merck Company Information Table 125. Merck Business Overview Table 126. Merck Respiratory Inhalable Biologics Sales (k units ), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Merck Respiratory Inhalable Biologics Product Portfolio Table 128. Merck Recent Development Table 129. North America Respiratory Inhalable Biologics Revenue by Type (2021-2026) & (US$ Million) Table 130. North America Respiratory Inhalable Biologics Revenue by Type (2027-2032) & (US$ Million) Table 131. North America Respiratory Inhalable Biologics Sales by Type (2021-2026) & (k units ) Table 132. North America Respiratory Inhalable Biologics Sales by Type (2027-2032) & (k units ) Table 133. North America Respiratory Inhalable Biologics Sales Price by Type (2021-2026) & (USD/unit) Table 134. North America Respiratory Inhalable Biologics Sales Price by Type (2027-2032) & (USD/unit) Table 135. North America Respiratory Inhalable Biologics Revenue by Application (2021-2026) & (US$ Million) Table 136. North America Respiratory Inhalable Biologics Revenue by Application (2027-2032) & (US$ Million) Table 137. North America Respiratory Inhalable Biologics Sales by Application (2021-2026) & (k units ) Table 138. North America Respiratory Inhalable Biologics Sales by Application (2027-2032) & (k units ) Table 139. North America Respiratory Inhalable Biologics Sales Price by Application (2021-2026) & (USD/unit) Table 140. North America Respiratory Inhalable Biologics Sales Price by Application (2027-2032) & (USD/unit) Table 141. North America Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 143. North America Respiratory Inhalable Biologics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 144. North America Respiratory Inhalable Biologics Sales by Country (2021 VS 2025 VS 2032) & (k units ) Table 145. North America Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 146. North America Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 147. North America Respiratory Inhalable Biologics Sales Price by Country (2021-2026) & (USD/unit) Table 148. North America Respiratory Inhalable Biologics Sales Price by Country (2027-2032) & (USD/unit) Table 149. United States Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 150. Canada Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 151. Mexico Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 152. Europe Respiratory Inhalable Biologics Revenue by Type (2021-2026) & (US$ Million) Table 153. Europe Respiratory Inhalable Biologics Revenue by Type (2027-2032) & (US$ Million) Table 154. Europe Respiratory Inhalable Biologics Sales by Type (2021-2026) & (k units ) Table 155. Europe Respiratory Inhalable Biologics Sales by Type (2027-2032) & (k units ) Table 156. Europe Respiratory Inhalable Biologics Sales Price by Type (2021-2026) & (USD/unit) Table 157. Europe Respiratory Inhalable Biologics Sales Price by Type (2027-2032) & (USD/unit) Table 158. Europe Respiratory Inhalable Biologics Revenue by Application (2021-2026) & (US$ Million) Table 159. Europe Respiratory Inhalable Biologics Revenue by Application (2027-2032) & (US$ Million) Table 160. Europe Respiratory Inhalable Biologics Sales by Application (2021-2026) & (k units ) Table 161. Europe Respiratory Inhalable Biologics Sales by Application (2027-2032) & (k units ) Table 162. Europe Respiratory Inhalable Biologics Sales Price by Application (2021-2026) & (USD/unit) Table 163. Europe Respiratory Inhalable Biologics Sales Price by Application (2027-2032) & (USD/unit) Table 164. Europe Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. Europe Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 166. Europe Respiratory Inhalable Biologics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 167. Europe Respiratory Inhalable Biologics Sales by Country (2021 VS 2025 VS 2032) & (k units ) Table 168. Europe Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 169. Europe Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 170. Europe Respiratory Inhalable Biologics Sales Price by Country (2021-2026) & (USD/unit) Table 171. Europe Respiratory Inhalable Biologics Sales Price by Country (2027-2032) & (USD/unit) Table 172. Germany Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 173. France Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 174. U.K. Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 175. Italy Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 176. Russia Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 177. Spain Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 178. Netherlands Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 179. Switzerland Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 180. Sweden Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 181. Poland Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 182. China Respiratory Inhalable Biologics Revenue by Type (2021-2026) & (US$ Million) Table 183. China Respiratory Inhalable Biologics Revenue by Type (2027-2032) & (US$ Million) Table 184. China Respiratory Inhalable Biologics Sales by Type (2021-2026) & (k units ) Table 185. China Respiratory Inhalable Biologics Sales by Type (2027-2032) & (k units ) Table 186. China Respiratory Inhalable Biologics Sales Price by Type (2021-2026) & (USD/unit) Table 187. China Respiratory Inhalable Biologics Sales Price by Type (2027-2032) & (USD/unit) Table 188. China Respiratory Inhalable Biologics Revenue by Application (2021-2026) & (US$ Million) Table 189. China Respiratory Inhalable Biologics Revenue by Application (2027-2032) & (US$ Million) Table 190. China Respiratory Inhalable Biologics Sales by Application (2021-2026) & (k units ) Table 191. China Respiratory Inhalable Biologics Sales by Application (2027-2032) & (k units ) Table 192. China Respiratory Inhalable Biologics Sales Price by Application (2021-2026) & (USD/unit) Table 193. China Respiratory Inhalable Biologics Sales Price by Application (2027-2032) & (USD/unit) Table 194. Asia Respiratory Inhalable Biologics Revenue by Type (2021-2026) & (US$ Million) Table 195. Asia Respiratory Inhalable Biologics Revenue by Type (2027-2032) & (US$ Million) Table 196. Asia Respiratory Inhalable Biologics Sales by Type (2021-2026) & (k units ) Table 197. Asia Respiratory Inhalable Biologics Sales by Type (2027-2032) & (k units ) Table 198. Asia Respiratory Inhalable Biologics Sales Price by Type (2021-2026) & (USD/unit) Table 199. Asia Respiratory Inhalable Biologics Sales Price by Type (2027-2032) & (USD/unit) Table 200. Asia Respiratory Inhalable Biologics Revenue by Application (2021-2026) & (US$ Million) Table 201. Asia Respiratory Inhalable Biologics Revenue by Application (2027-2032) & (US$ Million) Table 202. Asia Respiratory Inhalable Biologics Sales by Application (2021-2026) & (k units ) Table 203. Asia Respiratory Inhalable Biologics Sales by Application (2027-2032) & (k units ) Table 204. Asia Respiratory Inhalable Biologics Sales Price by Application (2021-2026) & (USD/unit) Table 205. Asia Respiratory Inhalable Biologics Sales Price by Application (2027-2032) & (USD/unit) Table 206. Asia Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 207. Asia Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 208. Asia Respiratory Inhalable Biologics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 209. Asia Respiratory Inhalable Biologics Sales by Country (2021 VS 2025 VS 2032) & (k units ) Table 210. Asia Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 211. Asia Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 212. Asia Respiratory Inhalable Biologics Sales Price by Country (2021-2026) & (USD/unit) Table 213. Asia Respiratory Inhalable Biologics Sales Price by Country (2027-2032) & (USD/unit) Table 214. Japan Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 215. South Korea Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 216. India Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 217. Australia Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 218. Taiwan Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 219. Southeast Asia Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 220. SAMEA Respiratory Inhalable Biologics Revenue by Type (2021-2026) & (US$ Million) Table 221. SAMEA Respiratory Inhalable Biologics Revenue by Type (2027-2032) & (US$ Million) Table 222. SAMEA Respiratory Inhalable Biologics Sales by Type (2021-2026) & (k units ) Table 223. SAMEA Respiratory Inhalable Biologics Sales by Type (2027-2032) & (k units ) Table 224. SAMEA Respiratory Inhalable Biologics Sales Price by Type (2021-2026) & (USD/unit) Table 225. SAMEA Respiratory Inhalable Biologics Sales Price by Type (2027-2032) & (USD/unit) Table 226. SAMEA Respiratory Inhalable Biologics Revenue by Application (2021-2026) & (US$ Million) Table 227. SAMEA Respiratory Inhalable Biologics Revenue by Application (2027-2032) & (US$ Million) Table 228. SAMEA Respiratory Inhalable Biologics Sales by Application (2021-2026) & (k units ) Table 229. SAMEA Respiratory Inhalable Biologics Sales by Application (2027-2032) & (k units ) Table 230. SAMEA Respiratory Inhalable Biologics Sales Price by Application (2021-2026) & (USD/unit) Table 231. SAMEA Respiratory Inhalable Biologics Sales Price by Application (2027-2032) & (USD/unit) Table 232. SAMEA Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 233. SAMEA Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 234. SAMEA Respiratory Inhalable Biologics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 235. SAMEA Respiratory Inhalable Biologics Sales by Country (2021 VS 2025 VS 2032) & (k units ) Table 236. SAMEA Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 237. SAMEA Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 238. SAMEA Respiratory Inhalable Biologics Sales Price by Country (2021-2026) & (USD/unit) Table 239. SAMEA Respiratory Inhalable Biologics Sales Price by Country (2027-2032) & (USD/unit) Table 240. Brazil Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 241. Argentina Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 242. Chile Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 243. Colombia Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 244. Peru Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 245. Saudi Arabia Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 246. Israel Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 247. UAE Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 248. Turkey Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 249. Iran Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 250. Egypt Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Table 251. Key Raw Materials Table 252. Raw Materials Key Suppliers Table 253. Respiratory Inhalable Biologics Distributors List Table 254. Respiratory Inhalable Biologics Customers List Table 255. Research Programs/Design for This Report Table 256. Authors List of This Report Table 257. Secondary Sources Table 258. Primary Sources List of Figures Figure 1. Respiratory Inhalable Biologics Image Figure 2. Global Respiratory Inhalable Biologics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Inhalable Biologics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Protein Drugs Image Figure 5. Peptide Drugs Image Figure 6. Monoclonal Antibodies Image Figure 7. Others Image Figure 8. Global Respiratory Inhalable Biologics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Respiratory Inhalable Biologics Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Retail Pharmacy Image Figure 12. Others Image Figure 13. Global Respiratory Inhalable Biologics Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Figure 15. Global Respiratory Inhalable Biologics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Respiratory Inhalable Biologics Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Respiratory Inhalable Biologics Revenue Market Share by Region (2021-2032) Figure 18. Global Respiratory Inhalable Biologics Sales (2021-2032) & (k units ) Figure 19. Global Respiratory Inhalable Biologics Sales by Region: 2021 VS 2025 VS 2032 (k units ) Figure 20. Global Respiratory Inhalable Biologics Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Respiratory Inhalable Biologics Sales YoY (2021-2032) & (k units ) Figure 22. Europe Respiratory Inhalable Biologics Sales YoY (2021-2032) & (k units ) Figure 23. China Respiratory Inhalable Biologics Sales YoY (2021-2032) & (k units ) Figure 24. Asia (Excluding China) Respiratory Inhalable Biologics Sales YoY (2021-2032) & (k units ) Figure 25. South America, Middle East and Africa Respiratory Inhalable Biologics Sales YoY (2021-2032) & (k units ) Figure 26. Global Respiratory Inhalable Biologics Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Respiratory Inhalable Biologics Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Respiratory Inhalable Biologics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Respiratory Inhalable Biologics Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Respiratory Inhalable Biologics Revenue Market Share by Type (2021-2032) Figure 32. Global Respiratory Inhalable Biologics Sales by Type (2021 VS 2025 VS 2032) & (k units ) Figure 33. Global Respiratory Inhalable Biologics Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Respiratory Inhalable Biologics Sales Market Share by Type (2021-2032) Figure 35. Global Respiratory Inhalable Biologics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Respiratory Inhalable Biologics Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Respiratory Inhalable Biologics Revenue Market Share by Application (2021-2032) Figure 38. Global Respiratory Inhalable Biologics Sales by Application (2021 VS 2025 VS 2032) & (k units ) Figure 39. Global Respiratory Inhalable Biologics Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Respiratory Inhalable Biologics Sales Market Share by Application (2021-2032) Figure 41. North America Respiratory Inhalable Biologics Revenue Share by Type (2021-2032) Figure 42. North America Respiratory Inhalable Biologics Sales Share by Type (2021-2032) Figure 43. North America Respiratory Inhalable Biologics Revenue Share by Application (2021-2032) Figure 44. North America Respiratory Inhalable Biologics Sales Share by Application (2021-2032) Figure 45. North America Respiratory Inhalable Biologics Revenue Share by Country (2021-2032) Figure 46. North America Respiratory Inhalable Biologics Sales Share by Country (2021-2032) Figure 47. Europe Respiratory Inhalable Biologics Revenue Share by Type (2021-2032) Figure 48. Europe Respiratory Inhalable Biologics Sales Share by Type (2021-2032) Figure 49. Europe Respiratory Inhalable Biologics Revenue Share by Application (2021-2032) Figure 50. Europe Respiratory Inhalable Biologics Sales Share by Application (2021-2032) Figure 51. Europe Respiratory Inhalable Biologics Revenue Share by Country (2021-2032) Figure 52. Europe Respiratory Inhalable Biologics Sales Share by Country (2021-2032) Figure 53. China Respiratory Inhalable Biologics Revenue Share by Type (2021-2032) Figure 54. China Respiratory Inhalable Biologics Sales Share by Type (2021-2032) Figure 55. China Respiratory Inhalable Biologics Revenue Share by Application (2021-2032) Figure 56. China Respiratory Inhalable Biologics Sales Share by Application (2021-2032) Figure 57. Asia Respiratory Inhalable Biologics Revenue Share by Type (2021-2032) Figure 58. Asia Respiratory Inhalable Biologics Sales Share by Type (2021-2032) Figure 59. Asia Respiratory Inhalable Biologics Revenue Share by Application (2021-2032) Figure 60. Asia Respiratory Inhalable Biologics Sales Share by Application (2021-2032) Figure 61. Asia Respiratory Inhalable Biologics Revenue Share by Country (2021-2032) Figure 62. Asia Respiratory Inhalable Biologics Sales Share by Country (2021-2032) Figure 63. SAMEA Respiratory Inhalable Biologics Revenue Share by Type (2021-2032) Figure 64. SAMEA Respiratory Inhalable Biologics Sales Share by Type (2021-2032) Figure 65. SAMEA Respiratory Inhalable Biologics Revenue Share by Application (2021-2032) Figure 66. SAMEA Respiratory Inhalable Biologics Sales Share by Application (2021-2032) Figure 67. SAMEA Respiratory Inhalable Biologics Revenue Share by Country (2021-2032) Figure 68. SAMEA Respiratory Inhalable Biologics Sales Share by Country (2021-2032) Figure 69. Respiratory Inhalable Biologics Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Respiratory Inhalable Biologics Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Protein Drugs
  • Peptide Drugs
  • Monoclonal Antibodies
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Vertex
  • Roche
  • Novartis
  • Chiesi
  • Teva
  • Prasco Laboratories
  • Viatris
  • Amgen
  • Sumitomo Dainippon
  • Zhengdatianqing
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Respiratory Inhalable Biologics Market by Type
  3. 1.2.1 Global Respiratory Inhalable Biologics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Protein Drugs
  5. 1.2.3 Peptide Drugs
  6. 1.2.4 Monoclonal Antibodies
  7. 1.2.5 Others
  8. 1.3 Respiratory Inhalable Biologics Market by Application
  9. 1.3.1 Global Respiratory Inhalable Biologics Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Retail Pharmacy
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Respiratory Inhalable Biologics Market Dynamics
  1. 2.1 Respiratory Inhalable Biologics Industry Trends
  2. 2.2 Respiratory Inhalable Biologics Industry Drivers
  3. 2.3 Respiratory Inhalable Biologics Industry Opportunities and Challenges
  4. 2.4 Respiratory Inhalable Biologics Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Respiratory Inhalable Biologics Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Respiratory Inhalable Biologics Revenue by Region
  3. 3.2.1 Global Respiratory Inhalable Biologics Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Respiratory Inhalable Biologics Revenue by Region (2021-2026)
  5. 3.2.3 Global Respiratory Inhalable Biologics Revenue by Region (2027-2032)
  6. 3.2.4 Global Respiratory Inhalable Biologics Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Respiratory Inhalable Biologics Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Respiratory Inhalable Biologics Sales by Region
  9. 3.4.1 Global Respiratory Inhalable Biologics Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Respiratory Inhalable Biologics Sales by Region (2021-2026)
  11. 3.4.3 Global Respiratory Inhalable Biologics Sales by Region (2027-2032)
  12. 3.4.4 Global Respiratory Inhalable Biologics Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Respiratory Inhalable Biologics Revenue by Manufacturers
  2. 4.1.1 Global Respiratory Inhalable Biologics Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Respiratory Inhalable Biologics Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Respiratory Inhalable Biologics Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Respiratory Inhalable Biologics Sales by Manufacturers
  6. 4.2.1 Global Respiratory Inhalable Biologics Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Respiratory Inhalable Biologics Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Respiratory Inhalable Biologics Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Respiratory Inhalable Biologics Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Respiratory Inhalable Biologics Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Respiratory Inhalable Biologics Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Respiratory Inhalable Biologics Manufacturers, Product Type & Application
  13. 4.7 Global Respiratory Inhalable Biologics Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Respiratory Inhalable Biologics Market CR5 and HHI
  16. 4.8.2 2025 Respiratory Inhalable Biologics Tier 1, Tier 2, and Tier 3
5 Respiratory Inhalable Biologics Market by Type
  1. 5.1 Global Respiratory Inhalable Biologics Revenue by Type
  2. 5.1.1 Global Respiratory Inhalable Biologics Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Respiratory Inhalable Biologics Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Respiratory Inhalable Biologics Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Respiratory Inhalable Biologics Sales by Type
  6. 5.2.1 Global Respiratory Inhalable Biologics Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Inhalable Biologics Sales by Type (2021-2032) & (k units )
  8. 5.2.3 Global Respiratory Inhalable Biologics Sales Market Share by Type (2021-2032)
  9. 5.3 Global Respiratory Inhalable Biologics Price by Type
6 Respiratory Inhalable Biologics Market by Application
  1. 6.1 Global Respiratory Inhalable Biologics Revenue by Application
  2. 6.1.1 Global Respiratory Inhalable Biologics Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Respiratory Inhalable Biologics Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Respiratory Inhalable Biologics Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Respiratory Inhalable Biologics Sales by Application
  6. 6.2.1 Global Respiratory Inhalable Biologics Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Respiratory Inhalable Biologics Sales by Application (2021-2032) & (k units )
  8. 6.2.3 Global Respiratory Inhalable Biologics Sales Market Share by Application (2021-2032)
  9. 6.3 Global Respiratory Inhalable Biologics Price by Application
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GSK Respiratory Inhalable Biologics Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 AstraZeneca
  8. 7.2.1 AstraZeneca Company Information
  9. 7.2.2 AstraZeneca Business Overview
  10. 7.2.3 AstraZeneca Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 AstraZeneca Respiratory Inhalable Biologics Product Portfolio
  12. 7.2.5 AstraZeneca Recent Developments
  13. 7.3 Boehringer Ingelheim
  14. 7.3.1 Boehringer Ingelheim Company Information
  15. 7.3.2 Boehringer Ingelheim Business Overview
  16. 7.3.3 Boehringer Ingelheim Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Boehringer Ingelheim Respiratory Inhalable Biologics Product Portfolio
  18. 7.3.5 Boehringer Ingelheim Recent Developments
  19. 7.4 Vertex
  20. 7.4.1 Vertex Company Information
  21. 7.4.2 Vertex Business Overview
  22. 7.4.3 Vertex Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Vertex Respiratory Inhalable Biologics Product Portfolio
  24. 7.4.5 Vertex Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Roche Respiratory Inhalable Biologics Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Respiratory Inhalable Biologics Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Chiesi
  38. 7.7.1 Chiesi Company Information
  39. 7.7.2 Chiesi Business Overview
  40. 7.7.3 Chiesi Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Chiesi Respiratory Inhalable Biologics Product Portfolio
  42. 7.7.5 Chiesi Recent Developments
  43. 7.8 Teva
  44. 7.8.1 Teva Company Information
  45. 7.8.2 Teva Business Overview
  46. 7.8.3 Teva Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Teva Respiratory Inhalable Biologics Product Portfolio
  48. 7.8.5 Teva Recent Developments
  49. 7.9 Prasco Laboratories
  50. 7.9.1 Prasco Laboratories Company Information
  51. 7.9.2 Prasco Laboratories Business Overview
  52. 7.9.3 Prasco Laboratories Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Prasco Laboratories Respiratory Inhalable Biologics Product Portfolio
  54. 7.9.5 Prasco Laboratories Recent Developments
  55. 7.10 Viatris
  56. 7.10.1 Viatris Company Information
  57. 7.10.2 Viatris Business Overview
  58. 7.10.3 Viatris Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Viatris Respiratory Inhalable Biologics Product Portfolio
  60. 7.10.5 Viatris Recent Developments
  61. 7.11 Amgen
  62. 7.11.1 Amgen Company Information
  63. 7.11.2 Amgen Business Overview
  64. 7.11.3 Amgen Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Amgen Respiratory Inhalable Biologics Product Portfolio
  66. 7.11.5 Amgen Recent Developments
  67. 7.12 Sumitomo Dainippon
  68. 7.12.1 Sumitomo Dainippon Company Information
  69. 7.12.2 Sumitomo Dainippon Business Overview
  70. 7.12.3 Sumitomo Dainippon Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Sumitomo Dainippon Respiratory Inhalable Biologics Product Portfolio
  72. 7.12.5 Sumitomo Dainippon Recent Developments
  73. 7.13 Zhengdatianqing
  74. 7.13.1 Zhengdatianqing Company Information
  75. 7.13.2 Zhengdatianqing Business Overview
  76. 7.13.3 Zhengdatianqing Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Zhengdatianqing Respiratory Inhalable Biologics Product Portfolio
  78. 7.13.5 Zhengdatianqing Recent Developments
  79. 7.14 Merck
  80. 7.14.1 Merck Company Information
  81. 7.14.2 Merck Business Overview
  82. 7.14.3 Merck Respiratory Inhalable Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Merck Respiratory Inhalable Biologics Product Portfolio
  84. 7.14.5 Merck Recent Developments
8 North America
  1. 8.1 North America Respiratory Inhalable Biologics Market Size by Type
  2. 8.1.1 North America Respiratory Inhalable Biologics Revenue by Type (2021-2032)
  3. 8.1.2 North America Respiratory Inhalable Biologics Sales by Type (2021-2032)
  4. 8.1.3 North America Respiratory Inhalable Biologics Price by Type (2021-2032)
  5. 8.2 North America Respiratory Inhalable Biologics Market Size by Application
  6. 8.2.1 North America Respiratory Inhalable Biologics Revenue by Application (2021-2032)
  7. 8.2.2 North America Respiratory Inhalable Biologics Sales by Application (2021-2032)
  8. 8.2.3 North America Respiratory Inhalable Biologics Price by Application (2021-2032)
  9. 8.3 North America Respiratory Inhalable Biologics Market Size by Country
  10. 8.3.1 North America Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Respiratory Inhalable Biologics Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Respiratory Inhalable Biologics Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Respiratory Inhalable Biologics Market Size by Type
  2. 9.1.1 Europe Respiratory Inhalable Biologics Revenue by Type (2021-2032)
  3. 9.1.2 Europe Respiratory Inhalable Biologics Sales by Type (2021-2032)
  4. 9.1.3 Europe Respiratory Inhalable Biologics Price by Type (2021-2032)
  5. 9.2 Europe Respiratory Inhalable Biologics Market Size by Application
  6. 9.2.1 Europe Respiratory Inhalable Biologics Revenue by Application (2021-2032)
  7. 9.2.2 Europe Respiratory Inhalable Biologics Sales by Application (2021-2032)
  8. 9.2.3 Europe Respiratory Inhalable Biologics Price by Application (2021-2032)
  9. 9.3 Europe Respiratory Inhalable Biologics Market Size by Country
  10. 9.3.1 Europe Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Respiratory Inhalable Biologics Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Respiratory Inhalable Biologics Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Respiratory Inhalable Biologics Market Size by Type
  2. 10.1.1 China Respiratory Inhalable Biologics Revenue by Type (2021-2032)
  3. 10.1.2 China Respiratory Inhalable Biologics Sales by Type (2021-2032)
  4. 10.1.3 China Respiratory Inhalable Biologics Price by Type (2021-2032)
  5. 10.2 China Respiratory Inhalable Biologics Market Size by Application
  6. 10.2.1 China Respiratory Inhalable Biologics Revenue by Application (2021-2032)
  7. 10.2.2 China Respiratory Inhalable Biologics Sales by Application (2021-2032)
  8. 10.2.3 China Respiratory Inhalable Biologics Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Respiratory Inhalable Biologics Market Size by Type
  2. 11.1.1 Asia Respiratory Inhalable Biologics Revenue by Type (2021-2032)
  3. 11.1.2 Asia Respiratory Inhalable Biologics Sales by Type (2021-2032)
  4. 11.1.3 Asia Respiratory Inhalable Biologics Price by Type (2021-2032)
  5. 11.2 Asia Respiratory Inhalable Biologics Market Size by Application
  6. 11.2.1 Asia Respiratory Inhalable Biologics Revenue by Application (2021-2032)
  7. 11.2.2 Asia Respiratory Inhalable Biologics Sales by Application (2021-2032)
  8. 11.2.3 Asia Respiratory Inhalable Biologics Price by Application (2021-2032)
  9. 11.3 Asia Respiratory Inhalable Biologics Market Size by Country
  10. 11.3.1 Asia Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Respiratory Inhalable Biologics Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Respiratory Inhalable Biologics Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Respiratory Inhalable Biologics Market Size by Type
  2. 12.1.1 SAMEA Respiratory Inhalable Biologics Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Respiratory Inhalable Biologics Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Respiratory Inhalable Biologics Price by Type (2021-2032)
  5. 12.2 SAMEA Respiratory Inhalable Biologics Market Size by Application
  6. 12.2.1 SAMEA Respiratory Inhalable Biologics Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Respiratory Inhalable Biologics Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Respiratory Inhalable Biologics Price by Application (2021-2032)
  9. 12.3 SAMEA Respiratory Inhalable Biologics Market Size by Country
  10. 12.3.1 SAMEA Respiratory Inhalable Biologics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Respiratory Inhalable Biologics Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Respiratory Inhalable Biologics Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Respiratory Inhalable Biologics Value Chain Analysis
  2. 13.1.1 Respiratory Inhalable Biologics Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Respiratory Inhalable Biologics Production Mode & Process
  6. 13.2 Respiratory Inhalable Biologics Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Respiratory Inhalable Biologics Distributors
  9. 13.2.3 Respiratory Inhalable Biologics Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst